The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1490
ISSUE1490
March 14, 2016
Zarxio - A Filgrastim Biosimilar
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Zarxio - A Filgrastim Biosimilar
March 14, 2016 (Issue: 1490)
The FDA has approved filgrastim-sndz (Zarxio –
Sandoz), a biosimilar of the recombinant human
granulocyte colony-stimulating factor filgrastim
(G-CSF; Neupogen), which has been available in the
US since 1991. Zarxio is the first biosimilar...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.